Category: News

TriReme Medical Announces Japanese Alliance

Pleasanton CA, Singapore, and Tokyo, January ___/PRNewswire/ — TriReme Medical, Inc. (TriReme) today announced that it has signed an exclusive distribution and sales agreement for

MerLion Signs License Agreement with Alcon to Develop & Commercialize Novel Finafloxacin Otic Product

Singapore, January 11, 2011 – MerLion Pharmaceuticals Pte Ltd today announced the signing of an agreement with Alcon Pharmaceuticals, Ltd. an affiliate of Alcon, Inc., by

Cloudpic Global Inc. Series $6Million to build virtual studios in Asia via Singapore

SINGAPORE, Jan. 5, 2011 – To enable millions of new artists in Asia to be part of worldclass content productions, Gobi Partners, Inc., a

Norderstedt – 29 November 2010 – Triton Water AG (“Triton”) has announced that EDB Investments (“EDBI”) of Singapore is investing in Triton, the leading provider of complete water-cycle industrial and maritime water treatment solutions, backed by zouk ventures.

Norderstedt – 29 November 2010 – Triton Water AG (“Triton”) has announced that EDB Investments (“EDBI”) of Singapore is investing in Triton, the leading provider

S*BIO’s JAK2 Inhibitor SB1518 Granted Orphan Drug Designation by European Commission for the Treatment of Myelofibrosis

Singapore, October 18, 2010 – S*BIO Pte Ltd today announced that the European Commission (EC) has granted orphan drug designation to SB1518, its potent and

TriReme Medical Announces $17M Series D Financing

Pleasanton, CA – October 11, 2010 – TriReme Medical, a leading developer of innovative catheters and stents for the treatment of complex vascular disease, announced

Inviragen & PharmaJet Receive $15.5M NIAID Contract to develop a needle-free Dengue Vaccine

Inviragen and PharmaJet announced the award of a five year, $15.5 million dollar contract from the National Institute of Allergy and Infectious Diseases (NIAID), part

S*BIO Initiates Canadian Phase 2 Clinical Trial of Oral Histone Deacetylase(HDAC) Inhibitor SB939

SINGAPORE, Sept. 27, 2010 – S*BIO Pte Ltd today announced the initiation of a Phase 2 clinical trial of SB939, its novel orally-active HDAC inhibitor,

SINGAPORE, Sept. 23, 2010 – S*BIO Pte Ltd today announced a US$5 million investment by Mitsui Ventures that will support the continued development of S*BIO’s clinical programs.

SINGAPORE, Sept. 23, 2010 – S*BIO Pte Ltd today announced a US$5 million investment by Mitsui Ventures that will support the continued development of S*BIO’s

Fluidigm Introduces World’s First Reusable Bio-Chip Architecture

Company Commits New Product Line to Support USDA Agricultural Research Service’ s “ Penny-perData-Point” Program for High Sample Throughput Genotyping